NEW YORK (GenomeWeb News) – GeneNews today said that it has struck an agreement with Health Diagnostic Laboratory and an unnamed sales organization to establish a jointly owned CLIA lab.
The joint venture, called innovative Diagnostic Laboratory, will initially focus on development and broader commercialization in the US of GeneNews' ColonSentry colorectal cancer test. GeneNews said it expects the lab to be functional and certified under the Clinical Lab Improvement Amendments Act in the third quarter.
In addition, the Toronto-based firm said that it has granted IDL an exclusive license for certain technology related to ColonSentry for development and commercialization throughout the US, excluding the States of New York and New Jersey. The partners in the JV will each receive a share of the revenues and profits generated by IDL, said GeneNews. Financial and further terms were not disclosed.
"IDL provides GeneNews with a US commercialization platform for the introduction of ColonSentry into the broader US market," Gailina Liew, president and COO of GeneNews, said in a statement. "We believe that Health Diagnostic Laboratory is an ideal partner for us in light of their experience and success in integrating high-throughput laboratory operations with sales capabilities on a national scale and look forward to working together to establish IDL as a leading clinical lab."
ColonSentry has been available in New York and New Jersey, through an agreement with Enzo Biochem, since 2012, but GeneNews has recently focused on driving commercialization beyond those two states.